Neurology for Practice, 2018, issue 5
Editorial
Slovo úvodem
prof. MUDr. Ivan Rektor, CSc., FCMA, FANA
Neurol. praxi. 2018;19(5):315 
Main topic
Slovo úvodem – hlavní téma
MUDr. Andrea Petrovičová
Neurol. praxi. 2018;19(5):320 | DOI: 10.36290/neu.2018.114
Acute migraine therapy in the emergency room
MUDr. Zuzana Dean, MUDr. Andrea Petrovičová
Neurol. praxi. 2018;19(5):321-325 | DOI: 10.36290/neu.2018.048
Migraine is common in adult as well as pediatric population. In our countries a neurologist is often called to the emergency roomfor differential diagnosis of headache and its therapy management in contrast with western countries, where acute managementof migraine is the premise of the emergency specialist. Local standard treatment protocols rarely exist. The current article reviewsdata on treatment of acute headache patients in the acute care setting.
Differential diagnosis of migraine
MUDr. Andrea Petrovičová
Neurol. praxi. 2018;19(5):326-329 | DOI: 10.36290/neu.2018.115
The symptoms of migraine are non-specific and can be present in many other primary and secondary headache disorders. Themigraine can be confused with other pathologies, alternative diagnoses for migraine may be mistake and conditions betweenmigraine and other diagnoses can posing as other conditions. Even experienced headache specialists may be challenged at timesin differential diagnosis of migraine.
Headache and cerebrovascular diseases
MUDr. Marek Krivošík
Neurol. praxi. 2018;19(5):330-334 | DOI: 10.36290/neu.2018.051
Headache is a common accompanying symptom in cerebrovascular diseases. Recognition of the features and identification ofheadaches in these conditions can aid diagnostic accuracy, therapeutic selections, and improve clinical care.
Methods of neurostimulation in the treatment of headaches
MUDr. Jana Múdra, MUDr. Silvia Petričková
Neurol. praxi. 2018;19(5):335-337 | DOI: 10.36290/neu.2018.116
Headache is one of the most common neurological symptoms and may have many causes. According to the ICHD-3 (The InternationalClassification of Headache Disorders 3rd edition), they are divided into three groups: primary headaches, secondaryheadaches, and painful cranial neuropathy and other facial pain and headaches. Pharmacological treatment of primary headachesis often difficult, insufficient and ineffective, and often carries various side effects. Recently, neurostimulation methods involvingnon-invasive and mini-invasive techniques, as well as deep brain stimulation, are used in patients with chronic primary headaches,which is used primarily in...
Review articles
Multiple sclerosis: treatment safety
doc. MUDr. Martin Vališ, Ph.D., MUDr. Zbyšek Pavelek
Neurol. praxi. 2018;19(5):338-342 | DOI: 10.36290/neu.2018.148
Multiple sclerosis is a chronic inflammatory autoimmune disease which affect central nervous system. Treatment initiation ofearly multiple sclerosis may postpone the development of disease progression and clinical activity, including magnetic resonancefindings and disablement. The aims of this paper is to describe options for treating multiple sclerosis and risks.
Low back pain and pelvic girdle pain in pregnancy
doc. MUDr. Blanka Adamová, Ph.D.
Neurol. praxi. 2018;19(5):343-348 | DOI: 10.36290/neu.2018.149
Pregnancy has a profound effect on a woman´s body including musculoskeletal system, specifically the axial skeleton. The developmentof low back pain and/or pelvic girdle pain (lumbopelvic pain) is a frequent consequence. Lumbopelvic pain has impacton the quality of life for women and is the frequent cause of sick leave. The prevalence of pelvic girdle pain ranges from 20% to65%, the prevalence of low back pain during pregnancy is about 50%. Lumbopelvic pain can be divided into three categories:low back pain, pelvic girdle pain, combined low back pain and pelvic girdle pain. The aim of this article is to summarize the recentdata about clinical manifestation,...
From the boundary of neurology
Natural course of multiple sclerosis could be positively intervened by optimal nutrition
prof. RNDr. Jan Krejsek, CSc.
Neurol. praxi. 2018;19(5):350-358 | DOI: 10.36290/neu.2018.117
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder of the central nervous systeme. It is characterizedby the loss of the homeostatic regulations of the immune systeme comprising both innate and specific T cell mediatedimmunity resulting in the abnormal functional polarisation of T cells into Th17 and Th1 subsets together with the participation ofabnormal B cells. Drugs used in clinical practice are targeting different steps of the inflammatory immunopathological process.The effect of this treatment could be enhanced by the optimal life style of MS patients. The inflammation in MS patients couldbe simply targeted by optimal...
When to consider inflammatory rheumatic disease in the differential diagnosis of back pain?
MUDr. Olga Šléglová
Neurol. praxi. 2018;19(5):359-364 | DOI: 10.36290/neu.2018.118
Aim: To highlight the need for early diagnosis of inflammatory rheumatic causes of back pain that, due to their rare occurrence,tend to be overlooked easily in patients with back pain.Summary: The group of inflammatory rheumatic diseases of the back (spondyloarthritides /SpA/) include autoimmune inflammatorydiseases wherein the inflammation affects the axial skeleton, root joints, and peripheral joints, predominantly in the lowerlimbs. The most common disease of the SpA group is ankylosing spondylitis (Bechterew’s disease). The diagnosis of ankylosingspondylitis has been based on the 1984 modified New York criteria which require radiographic...
Hepatic impairment during the treatment multiple sclerosis by dimethyl-fumarate
MUDr. Květoslava Aiglová, Ph.D., prof. MUDr. Jiří Ehrmann, CSc.
Neurol. praxi. 2018;19(5):365-368 | DOI: 10.36290/neu.2018.119
Dimethyl-fumarate (DMF) is a drug indicated for relapsing-remitting forms of multiple sclerosis. Treatment leads to reduction ofrelapses, delays invalidity and supresses manifestations of disease shown on MRI. Treatment by DMF has also side effects, includinggastrointestinal side effects and increase of liver enzymes activity. Clinical trials DEFINE and CONFIRM shown elevation of ALTin 6 % cases and discontinuation of treatment leaded do normalisation of liver tests. DMF is an effective and safe drug, possibleincreasing of liver tests does not mean serious risk, for which the treatment should by discontinued.
The role of physiotherapy in the prevention and treatment of diabetic polyneuropathy complications
Mgr. Mirka Bednaříková, Bc. Veronika Kužílková
Neurol. praxi. 2018;19(5):370-374 | DOI: 10.36290/neu.2018.120
Diabetic polyneuropathy is the most common chronic microvascular complication of diabetes mellitus. The number of type 2diabetic patients and subsequently diabetic polyneuropathy continues to grow, namely due to inappropriate lifestyle of currentpopulation. Over the life course the diabetic polyneuropathy affects more than 50 % of diabetics. Medical rehabilitation includingphysical therapy methods has an important role in influencing the symptoms and other complications of this serious disease aswell as in prevention of their progress.
Case report
The first administration of idarucizumab with subsequent intravenous thrombolysis and mechanical thrombectomy in Slovakia (a case report)
MUDr. Oto Petrík, MPH, MUDr. Iuliia Travkina, MUDr. Rastislav Bažík, MUDr. Ivan Vulev, PhD., MPH, FCIRSE, MUDr. Eva Unčovská
Neurol. praxi. 2018;19(5):376-379 | DOI: 10.36290/neu.2018.049
Intravenous thrombolysis as the basic causal therapy for acute ischaemic stroke in patients treated with novel oral anticoagulantsis contraindicated under certain circumstances. Dabigatran, as the only novel oral anticoagulant, has its specific antidote– the monoclonal antibody idarucizumab. Delivery of the antidote blocks the effect of anticoagulant therapy and allows foradministration of causal therapy for hyperacute-stage cerebral ischaemia (thrombolysis, mechanical thrombectomy). We reporta case of a 59-year-old female patient treated with dabigatran for a post-ischemic stroke state with a history of atrial fibrillationwho had a recurrence,...
Pharmacological profile
Ocrelizumab – pharmacoloical profile
doc. MUDr. Radomír Taláb, CSc., MUDr. Marika Talábová
Neurol. praxi. 2018;19(5):380-386 | DOI: 10.36290/neu.2018.121
Ocrelizumab (Ocrevus) is a humanized monoclonal antibody that was approved by the US Food and Drug Administration (FDA)on 28th March 2017 for the treatment of relapsing remitting multiple sclerosis (RRMS) and primarily progressive multiple sclerosis(PPMS) approved immunomodulatory treatment. European Medicines Agency (EMA) has recommended 10th November 2017OCR for the treatment of adult RRMS patients and early primary progressive MS patients in the European Union (EU) countries.In the Czech Republic, OCR was registered on 8th January 2017. The treatment is focused on mature B lymphocytes, immune cellsexpressing the protein CD20 molecule on their surface....
Information
Postavení nových antiepileptik v klinické praxi a jejich zaměnitelnost
prof. MUDr. Petr Marusič, Ph.D.
Neurol. praxi. 2018;19(5):387-388
Legal advice
Právní poradna
Neurol. praxi. 2018;19(5):389
Laudatio
Laudatium k sedmdesátinám doc. MUDr. Edvarda Ehlera, CSc.
Neurol. praxi. 2018;19(5):392
prof. MUDr. Ivan Rektor, CSc., FCMA, FANA, slaví sedmdesáté narozeniny
Neurol. praxi. 2018;19(5):393-394
Cameo
Joseph Jules Francois Félix Babinski
(17. 11. 1857–29. 10. 1932)
MUDr. Monika Chudáčková
Neurol. praxi. 2018;19(5):390-391